Teva Reports Positive Phase 1b Results for Vitiligo Antibody, Plans Phase 2b in 2026
Teva Pharmaceutical Industries announced encouraging results from its ongoing Phase 1b study of TEV-408, an antibody developed to treat vitiligo, a chronic skin condition. The antibody is administered subcutaneously every 12 weeks and demonstrated improved skin pigmentation in patients with non-segmental vitiligo, along with a favorable safety profile and no new safety signals. Approximately 75% of patients reported facial vitiligo improvement, with half describing significant or very significant progress, and 55% noted improvement across the entire body.
Richard Francis, Teva's President and CEO, highlighted TEV-408 as a key example of the company's innovative immunology pipeline, emphasizing its commitment to addressing unmet medical needs and returning to growth. Dr. Eric Hughes, Senior Vice President and Chief Medical Officer, stressed the broader impact of vitiligo on patients' self-perception and confidence, expressing optimism about the IL-15 pathway targeted by TEV-408 and its potential to offer a meaningful treatment alternative.
Earlier this year, Teva entered a partnership with Royalty Pharma to accelerate the drug's development. The agreement includes up to $500 million in funding from Royalty Pharma for ongoing development costs, with an option for an additional $425 million to support Phase 3 trials based on Phase 2b results. If successful and approved, Teva will pay royalties to Royalty Pharma on international sales of the medication. Teva plans to advance TEV-408 to Phase 2b trials in the fourth quarter of 2026.
